Cumberland Pharmaceuticals Inc. (CPIX)
USD 4.19
(3.2%)
USD 4.19
(3.2%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -710.85 Thousand USD | -155.32% |
| 2022 | 332.91 Thousand USD | 67.54% |
| 2021 | -857.83 Thousand USD | 44.93% |
| 2020 | -1.55 Million USD | 66.43% |
| 2019 | -4.64 Million USD | -20.74% |
| 2018 | -8.19 Million USD | -238.86% |
| 2017 | -1.13 Million USD | -197.08% |
| 2016 | 1.16 Million USD | -67.25% |
| 2015 | 3.56 Million USD | -38.49% |
| 2014 | 5.73 Million USD | 355.59% |
| 2013 | -2.26 Million USD | -122.64% |
| 2012 | 10.02 Million USD | -9.69% |
| 2011 | 11 Million USD | 44.53% |
| 2010 | 7.68 Million USD | 15.1% |
| 2009 | 6.67 Million USD | -19.71% |
| 2008 | 8.31 Million USD | 5.59% |
| 2007 | 7.87 Million USD | 161.07% |
| 2006 | 3.01 Million USD | 242.02% |
| 2005 | 882.38 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -663.81 Thousand USD | 91.65% |
| 2024 Q2 | 186.05 Thousand USD | 236.58% |
| 2023 Q2 | 2.26 Million USD | 39.56% |
| 2023 Q4 | -854.9 Thousand USD | -63.8% |
| 2023 FY | - USD | -155.32% |
| 2023 Q3 | -521.9 Thousand USD | -123.07% |
| 2023 Q1 | 1.62 Million USD | 194.22% |
| 2022 Q2 | -213.13 Thousand USD | -156.42% |
| 2022 Q3 | 1.27 Million USD | 699.42% |
| 2022 FY | - USD | 67.54% |
| 2022 Q4 | -1.72 Million USD | -234.68% |
| 2022 Q1 | 377.78 Thousand USD | 111.55% |
| 2021 Q4 | -3.27 Million USD | -578.0% |
| 2021 Q3 | -482.33 Thousand USD | -124.29% |
| 2021 Q2 | 1.98 Million USD | 118.54% |
| 2021 Q1 | 908.73 Thousand USD | 275.68% |
| 2021 FY | - USD | 44.93% |
| 2020 Q3 | -6667.00 USD | 98.2% |
| 2020 FY | - USD | 66.43% |
| 2020 Q1 | -664.05 Thousand USD | -478.9% |
| 2020 Q2 | -369.69 Thousand USD | 44.33% |
| 2020 Q4 | -517.27 Thousand USD | -7658.71% |
| 2019 FY | - USD | -20.74% |
| 2019 Q1 | 1.01 Million USD | 179.72% |
| 2019 Q4 | 175.25 Thousand USD | 120.29% |
| 2019 Q3 | -863.81 Thousand USD | -237.77% |
| 2019 Q2 | 627 Thousand USD | -38.25% |
| 2018 Q1 | -1.67 Million USD | -754.54% |
| 2018 FY | - USD | -238.86% |
| 2018 Q4 | -1.27 Million USD | -37.34% |
| 2018 Q3 | -927.34 Thousand USD | -5188.51% |
| 2018 Q2 | -17.53 Thousand USD | 98.95% |
| 2017 Q1 | 56.21 Thousand USD | 115.98% |
| 2017 FY | - USD | -197.08% |
| 2017 Q4 | -196.21 Thousand USD | -131.89% |
| 2017 Q3 | -84.61 Thousand USD | 91.17% |
| 2017 Q2 | -958.58 Thousand USD | -1805.12% |
| 2016 Q2 | 515.51 Thousand USD | 224.96% |
| 2016 Q3 | 795.38 Thousand USD | 54.29% |
| 2016 Q4 | -351.83 Thousand USD | -144.23% |
| 2016 FY | - USD | -67.25% |
| 2016 Q1 | 158.63 Thousand USD | -77.69% |
| 2015 Q2 | 1.31 Million USD | 111.26% |
| 2015 FY | - USD | -38.49% |
| 2015 Q1 | 621.76 Thousand USD | -58.71% |
| 2015 Q4 | 710.92 Thousand USD | -18.27% |
| 2015 Q3 | 869.86 Thousand USD | -33.78% |
| 2014 Q4 | 1.5 Million USD | -10.4% |
| 2014 FY | - USD | 355.59% |
| 2014 Q2 | 1.65 Million USD | 89.57% |
| 2014 Q1 | 870.52 Thousand USD | 141.1% |
| 2014 Q3 | 1.68 Million USD | 1.83% |
| 2013 FY | - USD | -122.64% |
| 2013 Q4 | -2.11 Million USD | -78.37% |
| 2013 Q1 | 1.7 Million USD | -50.09% |
| 2013 Q2 | -772.01 Thousand USD | -145.18% |
| 2013 Q3 | -1.18 Million USD | -53.81% |
| 2012 Q1 | 935.55 Thousand USD | -53.53% |
| 2012 FY | - USD | -9.69% |
| 2012 Q2 | 2.13 Million USD | 127.74% |
| 2012 Q3 | 3.31 Million USD | 55.36% |
| 2012 Q4 | 3.42 Million USD | 3.43% |
| 2011 Q2 | 3.94 Million USD | 130.51% |
| 2011 Q4 | 2.01 Million USD | -39.41% |
| 2011 FY | - USD | 44.53% |
| 2011 Q3 | 3.32 Million USD | -15.87% |
| 2011 Q1 | 1.71 Million USD | -32.36% |
| 2010 Q3 | 2.66 Million USD | 106.13% |
| 2010 FY | - USD | 15.1% |
| 2010 Q4 | 2.53 Million USD | -4.94% |
| 2010 Q1 | 1.1 Million USD | 17.07% |
| 2010 Q2 | 1.29 Million USD | 17.23% |
| 2009 Q2 | 776 Thousand USD | -66.7% |
| 2009 Q1 | 2.33 Million USD | 35.0% |
| 2009 Q3 | 2.59 Million USD | 234.22% |
| 2009 FY | - USD | -19.71% |
| 2009 Q4 | 941.74 Thousand USD | -63.69% |
| 2008 Q2 | 2.06 Million USD | 0.65% |
| 2008 Q1 | 2.04 Million USD | 26.19% |
| 2008 Q4 | 1.72 Million USD | -27.32% |
| 2008 Q3 | 2.37 Million USD | 15.27% |
| 2008 FY | - USD | 5.59% |
| 2007 Q2 | 2.32 Million USD | 52.2% |
| 2007 Q1 | 1.52 Million USD | 28.69% |
| 2007 Q4 | 1.62 Million USD | -32.16% |
| 2007 Q3 | 2.39 Million USD | 2.77% |
| 2007 FY | - USD | 161.07% |
| 2006 FY | - USD | 242.02% |
| 2006 Q1 | -1.12 Million USD | 0.0% |
| 2006 Q4 | 1.18 Million USD | -38.49% |
| 2006 Q2 | 1.02 Million USD | 190.95% |
| 2006 Q3 | 1.93 Million USD | 88.17% |
| 2005 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 100.231% |
| Embecta Corp. | 245.4 Million USD | 100.29% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 100.65% |
| Dynavax Technologies Corporation | 9.66 Million USD | 107.354% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 99.526% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 100.436% |
| PainReform Ltd. | -9.56 Million USD | 92.571% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 160.14% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 81.413% |
| SCYNEXIS, Inc. | 73.47 Million USD | 100.967% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 69.764% |
| Cosmos Health Inc. | -17.06 Million USD | 95.834% |
| Journey Medical Corporation | 1.92 Million USD | 137.004% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 81.413% |
| Safety Shot Inc | -12.18 Million USD | 94.166% |
| Alpha Teknova, Inc. | -25.53 Million USD | 97.217% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 99.553% |
| Bright Green Corporation | - USD | Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 100.683% |
| Theratechnologies Inc. | -10.31 Million USD | 93.107% |
| Harrow Health, Inc. | 9.72 Million USD | 107.311% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 84.291% |
| Biofrontera Inc. | -18.45 Million USD | 96.148% |
| DURECT Corporation | -24.68 Million USD | 97.12% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 100.723% |
| Cronos Group Inc. | -72.14 Million USD | 99.015% |
| OptiNose, Inc. | -15.55 Million USD | 95.429% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.923% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 98.03% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 102.706% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 101.973% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 81.877% |
| Radius Health, Inc. | 38.31 Million USD | 101.856% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 77.89% |
| ProPhase Labs, Inc. | -14.82 Million USD | 95.206% |
| Phibro Animal Health Corporation | 84.6 Million USD | 100.84% |
| Procaps Group S.A. | 104.02 Million USD | 100.683% |
| Alvotech | -484.86 Million USD | 99.853% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 91.539% |
| Viatris Inc. | 3.51 Billion USD | 100.02% |
| Rockwell Medical, Inc. | -4.69 Million USD | 84.856% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 29.758% |
| SIGA Technologies, Inc. | 84.15 Million USD | 100.845% |
| Tilray Brands, Inc. | -72.84 Million USD | 99.024% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 187.543% |
| Shineco, Inc. | -26.55 Million USD | 97.323% |
| PetIQ, Inc. | 81.48 Million USD | 100.872% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 80.35% |
| Incannex Healthcare Limited | -18.5 Million USD | 96.158% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 100.171% |
| Alimera Sciences, Inc. | 7.27 Million USD | 109.77% |
| Silver Spike Investment Corp. | 7.34 Million USD | 109.684% |
| Assertio Holdings, Inc. | -222.44 Million USD | 99.68% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 82.187% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 83.123% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 95.77% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 96.451% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 99.523% |
| Hempacco Co., Inc. | -12.77 Million USD | 94.435% |
| Talphera, Inc. | -9.84 Million USD | 92.777% |
| Alvotech | -484.86 Million USD | 99.853% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 100.917% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.145% |
| Currenc Group, Inc. | -1.9 Million USD | 62.598% |
| Kamada Ltd. | 21.53 Million USD | 103.301% |
| Indivior PLC | 66 Million USD | 101.077% |
| Evoke Pharma, Inc. | -7.29 Million USD | 90.252% |
| Flora Growth Corp. | -45.87 Million USD | 98.45% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 96.451% |
| Evolus, Inc. | -41.81 Million USD | 98.3% |
| HUTCHMED (China) Limited | 25.52 Million USD | 102.785% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 100.294% |
| Akanda Corp. | -27.73 Million USD | 97.437% |